Home > Press > Microfluidics Increases Already Sizable Presence in Europe, Middle East and Africa
Abstract:
Microfluidics, a wholly owned subsidiary of Microfluidics International Corporation (OTCBB: MFLU), has implemented new initiatives in order to better meet the needs of the growing biotechnology, pharmaceutical, chemical, cosmetics/personal care and food industries beyond the boundaries of North America, and to satisfy the increasing global demand for the company's innovative Microfluidizer® high shear fluid processors.
Microfluidics has maintained a presence in Europe, the Middle East and Africa (EMEA) since the mid-90's, through in-country sales representatives managed from a central sales office in Germany. As part of the first phase of its global distribution expansion plans, the company is now increasing that presence with new sales representatives and partnerships in France, Jordan, Kazakhstan, Portugal, Russia, Switzerland and Ukraine.
"We see tremendous opportunities for short- and long-term growth in all industries we currently serve throughout EMEA, as new applications requiring high quality and stable particle size reduction show up every day" said Xavier Leroy, Microfluidics' Vice President of Sales for Europe, Middle East and Africa. "By escalating our sales and service presence in these regions, we will be better equipped to meet the ever-increasing demand for our Microfluidizer processors and to help our customers in these countries achieve success with their own products and applications."
Microfluidics has amplified its sales force in EMEA with the addition of sales and service professionals who are not only knowledgeable about current market segments' needs and trends, but who also have a complete understanding of the cultures, economies and languages in the countries that they serve. Additionally, Microfluidics runs a testing lab at its EMEA sales office in Lampertheim, Germany where prospects from throughout the region can determine how a Microfluidizer processor would address their formulation challenges.
####
About Microfluidics
Microfluidics, a wholly owned subsidiary of Microfluidics International Corporation, is a supplier of advanced fluid processing equipment and reaction technology for laboratory, pilot scale and manufacturing applications. Microfluidics is a leader in innovative technology and comprehensive solutions for formulations requiring repeatability and for the production of uniformly distributed nanoparticles.
Microfluidics has been a worldwide supplier of Microfluidizer® high shear fluid processing systems to the biotechnology, pharmaceutical, chemical, cosmetics/personal care and food industries since 1984. As a leader in the field, Microfluidics has enabled numerous companies and institutions to formulate, validate and produce licensed drugs for the worldwide healthcare market.
Companies seeking to produce difficult-to-formulate products or to find better methods of bio-processing can take advantage of complimentary sample testing at one of three Microfluidics facilities. Visit www.microfluidicscorp.com, email or contact Microfluidics at 800.370.5452 for application information.
For more information, please click here
Contacts:
Gray & Rice Public Relations
Dinah Alobeid
617-367-0100 ext. 127
or
Microfluidics International Corporation
Brian LeClair
617-969-5452 ext. 245
Chief Financial Officer
Copyright © Business Wire 2008
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Microfluidics/Nanofluidics
Implantable device shrinks pancreatic tumors: Taming pancreatic cancer with intratumoral immunotherapy April 14th, 2023
Researchers design new inks for 3D-printable wearable bioelectronics: Potential uses include printing electronic tattoos for medical tracking applications August 19th, 2022
Oregon State University research pushes closer to new therapy for pancreatic cancer May 6th, 2022
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Alliances/Trade associations/Partnerships/Distributorships
Chicago Quantum Exchange welcomes six new partners highlighting quantum technology solutions, from Chicago and beyond September 23rd, 2022
University of Illinois Chicago joins Brookhaven Lab's Quantum Center June 10th, 2022
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||